Piot P, Van Dyck E
Antimicrob Agents Chemother. 1982 Jan;21(1):166-7. doi: 10.1128/AAC.21.1.166.
BRL 17421, a novel beta-lactam antibiotic, was tested in vitro against fastidious gram-negative bacteria and compared with amoxicillin and amoxicillin plus clavulanic acid. The compound showed good activity against Haemophilus influenzae (range of minimal inhibitory concentrations, 0.2 to 1 microgram/ml), Neisseria gonorrhoeae (0.007 to 0.5 microgram/ml), and Branhamella catarrhalis (0.03 to 0.1 microgram/ml). BRL 17421 exhibited excellent stability against the TEM-type beta-lactamase of H. influenzae and N. gonorrhoeae, and its activity was little affected by inoculum size. Minimal lethal concentrations of BRL 17421 for 10(7) colony-forming units of H. influenzae ranged between 0.5 and 4 micrograms/ml.
新型β-内酰胺抗生素BRL 17421针对苛养革兰氏阴性菌进行了体外测试,并与阿莫西林及阿莫西林加克拉维酸进行了比较。该化合物对流感嗜血杆菌(最低抑菌浓度范围为0.2至1微克/毫升)、淋病奈瑟菌(0.007至0.5微克/毫升)和卡他布兰汉菌(0.03至0.1微克/毫升)显示出良好活性。BRL 17421对流感嗜血杆菌和淋病奈瑟菌的TEM型β-内酰胺酶表现出优异的稳定性,其活性受接种量大小的影响很小。BRL 17421对10⁷个流感嗜血杆菌菌落形成单位的最低致死浓度在0.5至4微克/毫升之间。